Pradžia › Plazminių ląstelių vėžys › Texas
Plazminių ląstelių vėžys klinikiniai tyrimai Texas
7 tyrimai dėl Plazminių ląstelių vėžys ieško dalyvių vietose Texas.
Miestai Texas
Oficialus tyrimo tekstas (anglų kalba)
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- MD Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT04879043MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
- Baylor University Medical Center, Dallas
- Houston Methodist Cancer Center Infusion, Houston
- ir dar 9
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-24 · NCT06152575Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
- M D Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-08-20 · NCT06066359A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT05651932A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
- M D Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-11 · NCT05055063Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
- M D Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-15 · NCT05336383Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- Mays Cancer Center at UT Health San Antonio, San Antonio
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-20 · NCT05745285Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.